Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
LUPIN ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
LUPIN Mar-23 |
ACTAVIS Dec-18 |
LUPIN/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 799 | 16,134 | - | |
Low | Rs | 583 | 10,823 | - | |
Sales per share (Unadj.) | Rs | 365.8 | 3,957.7 | - | |
Earnings per share (Unadj.) | Rs | 9.8 | -1,274.8 | - | |
Cash flow per share (Unadj.) | Rs | 29.2 | 417.1 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 270.7 | 16,323.5 | - | |
Shares outstanding (eoy) | m | 454.98 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.9 | 3.4 | 55.5% | |
Avg P/E ratio | x | 70.2 | -10.6 | -664.2% | |
P/CF ratio (eoy) | x | 23.7 | 32.3 | 73.2% | |
Price / Book Value ratio | x | 2.6 | 0.8 | 309.2% | |
Dividend payout | % | 40.7 | 0 | - | |
Avg Mkt Cap | Rs m | 314,381 | 4,482,908 | 7.0% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 30,872 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,888.8 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,088.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,417 | 1,316,320 | 12.6% | |
Other income | Rs m | 1,509 | 25,172 | 6.0% | |
Total revenues | Rs m | 167,926 | 1,341,492 | 12.5% | |
Gross profit | Rs m | 17,206 | 34,494 | 49.9% | |
Depreciation | Rs m | 8,807 | 562,698 | 1.6% | |
Interest | Rs m | 2,743 | 75,959 | 3.6% | |
Profit before tax | Rs m | 7,165 | -578,991 | -1.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,666 | 0.0% | |
Tax | Rs m | 2,688 | -7,337 | -36.6% | |
Profit after tax | Rs m | 4,477 | -423,987 | -1.1% | |
Gross profit margin | % | 10.3 | 2.6 | 394.5% | |
Effective tax rate | % | 37.5 | 1.3 | 2,960.4% | |
Net profit margin | % | 2.7 | -32.2 | -8.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 124,513 | 539,886 | 23.1% | |
Current liabilities | Rs m | 92,654 | 477,601 | 19.4% | |
Net working cap to sales | % | 19.1 | 4.7 | 404.6% | |
Current ratio | x | 1.3 | 1.1 | 118.9% | |
Inventory Days | Days | 26 | 20 | 133.9% | |
Debtors Days | Days | 98 | 66 | 148.2% | |
Net fixed assets | Rs m | 103,490 | 149,000 | 69.5% | |
Share capital | Rs m | 910 | 0 | - | |
Net worth | Rs m | 123,156 | 5,429,205 | 2.3% | |
Long term debt | Rs m | 275 | 1,911,820 | 0.0% | |
Total assets | Rs m | 228,003 | 8,487,083 | 2.7% | |
Interest coverage | x | 3.6 | -6.6 | -54.5% | |
Debt to equity ratio | x | 0 | 0.4 | 0.6% | |
Sales to assets ratio | x | 0.7 | 0.2 | 470.6% | |
Return on assets | % | 3.2 | -4.1 | -77.2% | |
Return on equity | % | 3.6 | -7.8 | -46.5% | |
Return on capital | % | 8.0 | -4.8 | -165.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 18,972 | 470,272 | 4.0% | |
From Investments | Rs m | -12,868 | 258,353 | -5.0% | |
From Financial Activity | Rs m | -3,373 | -807,127 | 0.4% | |
Net Cashflow | Rs m | 2,732 | -78,110 | -3.5% |
Compare LUPIN With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare LUPIN With: SAKAR HEALTHCARE MEDICAMEN BI GLENMARK PHARMA PARNAX LAB SUN PHARMA
Asian markets traded higher on Tuesday following overnight gain on Wall Street.